Scarica l'app Stockscreener
27.16
2.86%
-0.80
Pre-mercato:
26.01
-1.15
-4.23%
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
MapLight Therapeutics (MPLT) Surges 3.31% as Positive Momentum BuildsHull Moving Average - newsline.com
MPLT Q1 2026 Earnings: EPS Misses Estimates by 20% as Pre-Revenue Biotech Continues Clinical Progress - newsline.com
MapLight Therapeutics (MPLT) Drops Over 6% as Key Support Level NearsVWAP Breakout - newsline.com
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - AOL.com
MPLT Maintained by Stifel -- Price Target Raised to $36.00 - GuruFocus
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Stifel raises MapLight Therapeutics price target on drug potential By Investing.com - Investing.com Canada
MPLT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - newsline.com
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - AOL.com
MPLT Options Volatility — NASDAQ:MPLT - TradingView
MPLT Options Chain — NASDAQ:MPLT - TradingView
MapLight Stock Slips Ahead of August Drug Update - Bez Kabli
MPLT Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Development SpendingEarnings Call Q&A - The Legal Advocate
MPLT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
MPLT Initiated Coverage by UBS -- Rating Set to Buy, Target at $48 - GuruFocus
MapLight Therapeutics Rises 2.4%, Nearing Key Resistance Level (MPLT)Resistance Breakout Stocks - The Legal Advocate
MapLight Therapeutics (MPLT) Tests Key Support After 1.8% DeclineSeasonality Effect - The Legal Advocate
Nan Fung Group Holdings Ltd's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus
MPLT Initiated Coverage On by Craig-Hallum -- Rating Set to Buy - GuruFocus
MapLight Therapeutics (MPLT) Q1 2026 Stumbles — EPS $-1.34 Misses TargetPro Trader Picks - Newser
Craig-Hallum initiates MapLight Therapeutics stock with buy rating By Investing.com - Investing.com Canada
MapLight Therapeutics Q1 2026 Earnings: Wider Loss than Anticipated, Yet Shares Climb on Pipeline OptimismRevenue Surprise History - The Legal Advocate
Analyst Reiterates Buy on MapLight, Maintains $37 Price Target on Confidence in ML-007 and Pipeline Upside - TipRanks
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock By Investing.com - Investing.com Nigeria
MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing - Moomoo
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock - Investing.com
MapLight Therapeutics (MPLT) CEO sells 118K shares in pre-planned trades - Stock Titan
MapLight Therapeutics, Inc.Common Stock (NQ: MPLT - The Chronicle-Journal
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged - TipRanks
T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics - Stock Titan
A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $35 to $45 - Moomoo
MPLT SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36, Implies 23% Upside - TradingView
MapLight (MPLT) Reports Progress in Clinical Trials and Early-St - GuruFocus
MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses - TipRanks
MapLight Therapeutics 1Q Loss/Shr $1.34 >MPLT - Moomoo
TradingKey - TradingKey
[10-Q] MapLight Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
MapLight Therapeutics (MPLT) widens Q1 loss as key Phase 2 readouts near - Stock Titan
What $395M in cash means for MapLight’s schizophrenia, autism trials - Stock Titan
MapLight Therapeutics (MPLT) Q4 2025 Earnings: Miss Sparks ConcernNet Profit Margin - newsline.com
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):